Oncology pharmacists discuss myelofibrosis management, focusing on anemia, JAK inhibitors, and improving patient outcomes through tailored care.
Ami Ali, PharmD, BCOP
Advertisement
Articles by Ami Ali, PharmD, BCOP
Explore expert insights on managing myelofibrosis, focusing on anemia, JAK inhibitors, and enhancing patient care for better outcomes.
BV-R2 combination shows survival benefit across high-risk subgroups.
The FDA approved acalabrutinib as a frontline option for untreated mantle cell lymphoma.
The approval marks a significant milestone in the treatment of a rare and aggressive subtype of acute leukemia.
Pharmacists will play a significant role in TKI adherence rates among patients.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
Reimagining Pharmacy: A Call to Action for Pharmacy Professionals
2
FDA Approves Milestone Oral Therapy for Adults With Thalassemia Anemia
3
Lowering Blood Glucose in Prediabetes May Prevent Heart Attacks and Heart Failure
4
Experimental Multistage Malaria Vaccine Demonstrates Promising Protection in Early Trial
5